ERBB2 and cancer: Targeting this pathway with pan-RAR antagonists may impede cancer progression and prolong patient survival.328 Similarly, EGFR-mutated NSCLC patients develop resistance to EGFR tyrosine kinase inhibitors (TKIs), where upregulation of CD70 in resistant cells is considered an early event in tumor resistance evolution, suggesting CD70 as a therapeutic target for acquired EGFR TKI resistance in EGFR-mutated tumors.329 In recent years, HER2-targeted therapies such as pertuzumab and trastuzumab have made significant strides in improving the prognosis of various cancer types.